Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PIK3CA Related Overgrowth Spectrum”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Testing effectiveness (Phase 2)Study completedNCT02428296
What this trial is testing

Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)Growth DisorderGenetics
National Human Genome Research Institute (NHGRI) 39
Not applicableAvailableNCT04085653
What this trial is testing

Managed Access Programs for BYL719, Alpelisib

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)Breast Cancer
Novartis Pharmaceuticals
Not applicableStudy completedNCT05294289
What this trial is testing

Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study

Who this might be right for
PIK3CA-related Overgrowth Spectrum
Novartis Pharmaceuticals 77
Not applicableNo Longer AvailableNCT03317366
What this trial is testing

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

Who this might be right for
Proteus SyndromePIK3CA-Related Overgrowth Spectrum (PROS)Growth Disorders
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Testing effectiveness (Phase 2)Active Not RecruitingNCT04980872
What this trial is testing

The Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
Merck Sharp & Dohme LLC 60
Testing effectiveness (Phase 2)Looking for participantsNCT06997588
What this trial is testing

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Who this might be right for
PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals 104
Not applicableStudy completedNCT05563831
What this trial is testing

National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

Who this might be right for
PIK3CA-related Overgrowth SpectrumCLOVES SyndromeKlippel Trenaunay Syndrome+6 more
Institut National de la Santé Et de la Recherche Médicale, France 28
Testing effectiveness (Phase 2)Looking for participantsNCT06789913
What this trial is testing

Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic MalformationsVascular Malformations+4 more
Relay Therapeutics, Inc. 277
Not applicableStudy completedNCT04285723
What this trial is testing

Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals 57
Testing effectiveness (Phase 2)Ended earlyNCT03094832
What this trial is testing

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04589650
What this trial is testing

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Who this might be right for
PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals 206
Not applicableStudy completedNCT07222423
What this trial is testing

The Epidemiology and Hospital Management of Patients With PROS in France

Who this might be right for
PIK3CA-Related Overgrowth Spectrum
Novartis Pharmaceuticals 3,605
Testing effectiveness (Phase 2)Looking for participantsNCT05983159
What this trial is testing

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

Who this might be right for
Slow-Flow Vascular MalformationFast-Flow Vascular MalformationVascular Malformations+15 more
Murdoch Childrens Research Institute 50
Testing effectiveness (Phase 2)Looking for participantsNCT06975618
What this trial is testing

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)PIK3CA-related Vascular Malformations (PRVM)
Haihe Biopharma Co., Ltd. 141
Not applicableLooking for participantsNCT00001403
What this trial is testing

Study of Proteus Syndrome and Related Congenital Disorders

Who this might be right for
Proteus SyndromePIK3CA Related Overgrowth Spectrum
National Human Genome Research Institute (NHGRI) 1,500
Testing effectiveness (Phase 2)Active Not RecruitingNCT04980833
What this trial is testing

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

Who this might be right for
PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals 41